Literature DB >> 17709137

Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells.

Ping Xie1, Yun-Fen Shen, Yuan-Ping Shi, Shu-Mei Ge, Zhong-Hua Gu, Jue Wang, Hui-Jun Mu, Bin Zhang, Wei-Zhen Qiao, Ke-Ming Xie.   

Abstract

Ceramide, as a second messenger, initiates one of the major signal transduction pathways in tumor apoptosis. Glucosylceramide synthase (GCS) catalyzes glycosylation of ceramide and produces glucosylceramide. Through GCS, ceramide glycosylation allows cellular escape from ceramide-induced programmed cell death. Here we investigated the expression of GCS in human leukemia cells and an association between GCS and multidrug resistance of leukemia cells. Using RT-PCR technique the level of GCS gene was detected in 65 clinical multidrug resistance/non-resistance cases with leukemia, and in K562 and K562/A02 cell lines. AlamarBlue Assay was applied to confirm the multidrug resistant of K562/A02 cells. PPMP, which is a chemical inhibitor for GCS, was used to determine the relationship between GCS and drug-resistance in K562/A02 cells. In addition, multidrug resistance gene (mdr1), Bcl-2 and Bax mRNA was also analyzed by RT-PCR. The expression of GCS and mdr1 mRNA in clinic multidrug resistance samples exhibited significantly increased compared with clinic drug sensitive group (P<0.05). There was the positive correlation both the expression of GCS and mdr1 genes in leukemia samples (P<0.01, gamma=0.7). AlamarBlue Assay showed that the K562/A02 cell line was 115-fold more resistant to adriamycin and 36-fold more resistant to vincristine compared with drug-sensitive K562 cell line. There also was significant expression difference of GCS and mdr1 genes between K562 and K562/A02 cells. Bcl-2 gene exhibited higher expressions whatever in clinic drug-resistance samples or K562/A02 cells, whereas the expressions of Bax gene were higher in drug-sensitive samples and K562 cells. PPMP increased sensitivity to adriamycin toxicity by inhibiting GCS in K562/A02 cells. Therefore, it is suggested that a high level of GCS in leukemia is possible contributed to multidrug resistance of leukemia cells. Abnormally expressions of the genes in associated with cell apoptosis might be one of the main molecular pathology mechanisms of multidrug resistance caused by GCS gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709137     DOI: 10.1016/j.leukres.2007.07.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  30 in total

1.  Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Authors:  Li-Pin Kao; Samy A F Morad; Traci S Davis; Matthew R MacDougall; Miki Kassai; Noha Abdelmageed; Todd E Fox; Mark Kester; Thomas P Loughran; Jose' L Abad; Gemma Fabrias; Su-Fern Tan; David J Feith; David F Claxton; Sarah Spiegel; Kelsey H Fisher-Wellman; Myles C Cabot
Journal:  J Lipid Res       Date:  2019-07-30       Impact factor: 5.922

Review 2.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

Review 3.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 4.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

5.  Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Ping Xie; Xin Gu; Armando E Giuliano; Myles C Cabot
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

6.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

7.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

8.  Dysregulated sphingolipid metabolism in endometriosis.

Authors:  Yie Hou Lee; Chin Wen Tan; Abhishek Venkatratnam; Chuen Seng Tan; Liang Cui; Seong Feei Loh; Linda Griffith; Steven R Tannenbaum; Jerry Kok Yen Chan
Journal:  J Clin Endocrinol Metab       Date:  2014-06-24       Impact factor: 5.958

9.  Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.

Authors:  Samy A F Morad; Traci S Davis; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Leuk Res       Date:  2015-07-02       Impact factor: 3.156

10.  A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Authors:  Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.